NEO212

Developed for: cervical cancer · colorectal cancer · cutaneous neuroendocrine carcinoma · diffuse astrocytoma · esophageal squamous cell carcinoma · gastric cancer · gastroesophageal junction adenocarcinoma · head and neck squamous cell carcinoma
+7 more
· IDH-wildtype glioblastoma · melanoma · metastatic malignant neoplasm in the brain · non-small cell lung carcinoma · renal cell carcinoma · small cell lung carcinoma · urothelial carcinoma
Investigated by: Neonc Technologies, Inc.

today NCT06047379 · Ph 1/2

2024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT06047379	Nov 2023 → Feb 2027 expected	IDH-wildtype glioblastoma, cervical cancer, colorectal cancer, cutaneous neuroendocrine carcinoma +11	Neonc Technologies, Inc.	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	NEO212	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06047379 ↗